Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Accelerated pace of innovation: HealthGen awarded "Most Investment Value Listed Company" at the 17th Crystal Ball Awards
Published Time：
2023-12-30
On December 29, 2023, the 2023 Capital Market Crystal Ball Award list, initiated by the Securities Market Weekly, was officially released. HealthGen (600380.SZ) stood out from a number of participating listed companies, winning the "2023 Most Investment Value Listed Company" award, thanks to its outstanding independent R&D capabilities as a core driving force.
HealthGen is an innovative R&D-oriented comprehensive pharmaceutical group focusing on the health industry. In recent years, under the leadership of Chairman Zhu Baoguo, the company has taken product innovation as its core strategic development, continuously strengthening its independent R&D capabilities, and focusing its resources on promoting product innovation. The company possesses a series of core technologies and patents that help enhance product competitiveness and market position. HealthGen's core technologies cover multiple fields, including respiratory, anti-infection, anti-tumor, gonadotropin, digestive, and neurological areas, driving the company to continuously make breakthroughs in innovative drugs and high-end preparations, accelerating its transformation and upgrading to innovation. In the raw material medicine sector, HealthGen will vigorously promote the independent production and substitution of key products, especially raw materials in the inhalation sector, and focus on tackling core technologies and key intermediates. The company will also continuously invest in and explore innovative varieties.
As one of the high-tech industries with the most development potential and innovative vitality, the biopharmaceutical industry sees HealthGen emphasizing product innovation and continuously launching high-quality products that meet market demand.
Not long ago, the company signed an exclusive license agreement with Guangzhou Fermi Technology Co., Ltd. (hereinafter referred to as "Fermi") for the development of the analgesic new drug FZ008-145. Information shows that FZ008-145 is a small molecule innovative drug, a highly selective second-generation Nav1.8 (voltage-gated sodium channel 1.8) inhibitor, with the advantages of high efficacy and non-addictive analgesia. In October this year, FZ008-145 submitted an IND application to the CDE. HealthGen recently stated that the product collaboration is progressing as planned.
Regarding the future prospects of FZ008-145, both parties are positive and optimistic. Mr. Yu Xiong, President of HealthGen Group, said: "HealthGen continues to increase investment in innovative drug R&D, and the cooperation with Fermi enriches our layout in the analgesic drug R&D pipeline. We are optimistic about the future potential of FZ008-145 and will accelerate its clinical development in the future." Mr. Deng Daiguo, founder of Fermi, said: "We are very pleased to cooperate with a leading pharmaceutical company like HealthGen. As the second globally second-generation highly selective Nav1.8 inhibitor with better PK properties, we have great expectations and confidence in its development."
The company has a professional R&D team that continuously carries out technological innovation and product improvement. Market Competitiveness: Possesses a rich product line to meet the needs of different consumers; focuses on product quality and safety, ensuring product quality and safety through a strict quality control and certification system; focuses on brand building and market promotion to enhance brand awareness and reputation.
In the market, HealthGen actively expands diversified businesses, increases R&D investment, and continuously launches innovative and competitive products; establishes strategic partnerships with well-known domestic and foreign enterprises to jointly promote the development of the health industry; actively expands online sales channels and strengthens cooperation with e-commerce platforms to improve product market coverage.
With the improvement of people's health awareness and the increase in consumption capacity, the demand for health foods and health products will continue to grow steadily. The health food market is a continuously growing industry. At the same time, with the support of health industry policies and the improvement of national income levels, the company is expected to achieve broader development in both domestic and international markets.
From: Securities Market Weekly
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.